InnoUp
Private Company
Funding information not available
Overview
InnoUp is a private, clinical-stage biotech leveraging its proprietary nanoparticle encapsulation platform to develop novel oral drug delivery solutions. Its pipeline includes two clinical-stage programs: an oral peanut allergy vaccine (INP20) and an oral formulation of paclitaxel for breast cancer (INP12). The company's technology aims to enhance drug bioavailability and enable mucosal immunization, positioning it in the high-growth nanomedicine and drug delivery sectors.
Technology Platform
Patented encapsulation platform based on biocompatible, bioadhesive nanoparticles for sustained oral drug delivery and mucosal immunization.
Opportunities
Risk Factors
Competitive Landscape
Competes with other nanomedicine and drug delivery specialists, as well as large pharma developing oral formulations. In peanut allergy, competes with approved oral immunotherapy and other desensitization approaches. In oral paclitaxel, faces technical and commercial competition from other encapsulation technologies and novel taxane derivatives.